November 25, 2020 -- Moderna has announced that the European Commission (EC) has agreed to secure 80 million doses of its COVID-19 vaccine messenger RNA (mRNA)-1273.
The commission has the option to increase its purchase to up to 160 million doses. The agreement will be finalized after the European Union member states review it. Delivery of the doses could begin as early as the first quarter 2021 if the vaccine is approved by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), which began a rolling review of mRNA-1273 on November 17.
On November 16, it was announced that Moderna's vaccine had a 94.5% efficacy in a phase III clinical trial.